CD19 and chronic myelogenous leukemia, BCR-ABL1 positive: For the target cell, NALM-6 (derived from B-acute lymphoblastic leukemia), and K562/CD19 cells (derived from chronic myeloid leukemia, lentivirally transduced with CD19) were chosen, and their CD19 expressions were confirmed by flow cytometry (Fig 1C).